<DOC>
	<DOCNO>NCT02756637</DOCNO>
	<brief_summary>The purpose study perform secondary analysis SWOG 8710 ass NLRs value biomarker . Specifically , investigator test two hypothesis : 1 ) baseline NLR correlate overall survival curative treatment BC 2 ) baseline NLR correlate survival benefit NAC . The study look data participant SWOG 8710 study .</brief_summary>
	<brief_title>Neutrophil-to-Lymphocyte Ratio Bladder Cancer : A Secondary Biomarker Analysis SWOG 8710</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1 . SWOG 8710 original trial inclusion criterion include : Nodenegative , muscleinvasive transitional cell carcinoma bladder , T2T4aN0M0 per AJCC 4th edition stag manual . SWOG performance status 0 1 Adequate organ function lab criterion ( WBC &gt; 4,000 cells/mm3 , platelet &gt; 150,000 cells/mm3 , creatinine &lt; 1.5 md/dL ( men ) &lt; 1.3 md/dL ( woman ) , baseline liver test &lt; 2 time normal limit ) 2 . Inclusion criterion secondary analysis : Eligible original SWOG 8710 trial Had complete blood count differential prior first treatment ( radical cystectomy NAC ) . 1 . SWOG 8710 original trial exclusion criterion include : No age restriction Previous concomitant malignancy bladder cancer basal cell skin cancer Prior pelvic radiation Metastatic incurable disease Laboratory value exceed detail 3.1.c 2 . Exclusion criterion secondary analysis : Ineligibility original SWOG 8710 study Lack complete blood count differential prior first treatment ( cystectomy NAC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>